A nurse is teaching a client who has a new prescription for dextromethorphan. The nurse should instruct the client to monitor for which of the following adverse effects when taking dextromethorphan?
Palpitations
Hypertension
Ataxia
Diarrhea
The Correct Answer is C
A) Palpitations: While palpitations can be concerning for many medications, they are not a commonly reported side effect of dextromethorphan. This medication primarily acts as a cough suppressant and does not typically have cardiovascular effects that would lead to palpitations. Therefore, clients should not primarily monitor for this side effect when taking dextromethorphan.
B) Hypertension: Dextromethorphan is not generally associated with causing hypertension. Its main action is to suppress the cough reflex, and it does not typically influence blood pressure levels. Patients taking this medication should focus on other side effects rather than worrying about hypertension.
C) Ataxia: Ataxia, or impaired coordination, is a notable adverse effect associated with dextromethorphan, especially at higher doses or when combined with other central nervous system depressants like alcohol. This side effect can lead to dizziness and increased risk of falls or accidents, making it important for clients to be aware of their coordination and alertness levels while on this medication. Advising patients to avoid driving or operating heavy machinery if they experience ataxia is essential for their safety.
D) Diarrhea: Diarrhea is not a common adverse effect of dextromethorphan. The medication is primarily used for its antitussive properties, and gastrointestinal disturbances like diarrhea are generally not associated with its use. If patients experience gastrointestinal symptoms while taking this medication, they may need to consider other factors or medications that could be contributing to those symptoms.
Nursing Test Bank
Naxlex Comprehensive Predictor Exams
Related Questions
Correct Answer is A
Explanation
A. Use this inhaler 15 minutes prior to physical activity: This is the correct recommendation for cromolyn. It is a mast cell stabilizer that helps prevent asthma symptoms by inhibiting the release of inflammatory mediators. Using it before physical activity can help minimize exercise-induced bronchospasm.
B. Tachycardia is an adverse effect associated with this medication: This statement is misleading. Cromolyn is not typically associated with tachycardia as an adverse effect. Unlike bronchodilators, which can cause increased heart rate, cromolyn primarily works to stabilize mast cells and has a different side effect profile.
C. This medication should not be discontinued abruptly: While it is generally good practice to consult a healthcare provider before stopping any asthma medication, cromolyn does not have a significant risk of withdrawal symptoms like corticosteroids might. It is more important to maintain regular use for effectiveness rather than fear abrupt discontinuation.
D. Injections are required weekly to properly prevent asthma attacks: This statement is incorrect. Cromolyn is administered via inhalation, not by injection, and does not require weekly injections. Patients should use the inhaler as prescribed, typically several times a day, depending on their individual treatment plan.
Correct Answer is C
Explanation
A. Inhibits the production of leukotrienes and histamine, preventing further asthma attacks: This statement is misleading. Omalizumab does not directly inhibit the production of leukotrienes or histamine; rather, it works by targeting IgE, which is involved in the allergic response.
B. Inhibits mast cells from releasing histamine, preventing further asthma attacks: While omalizumab does reduce the overall allergic response, it does so by binding to IgE rather than directly inhibiting mast cell activity. Therefore, this description does not accurately represent its primary mechanism of action.
C. Selectively binds to IgE, reducing allergic mediators and asthma attacks: This statement correctly describes the mechanism of action of omalizumab. By binding to immunoglobulin E (IgE), omalizumab prevents IgE from attaching to mast cells and basophils, thus reducing the release of allergic mediators that contribute to asthma attacks.
D. Stimulates alpha-adrenergic receptors to assist in reduction of allergic-related symptoms: This statement is incorrect. Omalizumab does not stimulate alpha-adrenergic receptors; such action is associated with certain bronchodilators. Omalizumab specifically targets IgE to mitigate allergic responses.
Whether you are a student looking to ace your exams or a practicing nurse seeking to enhance your expertise , our nursing education contents will empower you with the confidence and competence to make a difference in the lives of patients and become a respected leader in the healthcare field.
Visit Naxlex, invest in your future and unlock endless possibilities with our unparalleled nursing education contents today
Report Wrong Answer on the Current Question
Do you disagree with the answer? If yes, what is your expected answer? Explain.
Kindly be descriptive with the issue you are facing.